Figure 3.

Patients with HOXA9^lo show slightly inferior EFS than patients with HOXA9^hi in a cohort of 43 infant patients with t(4;11) pro-B ALL

(A) Patients were divided into a group that displayed no event within 5 years from diagnosis (n = 12), and a group with an event within the same time frame (n = 23). Subsequently, patients were assigned to the respective HOXA9 transcription level and divided into a HOXA9^lo and a HOXA9^hi subgroup.

(B) Kaplan-Meier curves of the patients with HOXA9^lo vs HOXA9^hi visualize the slightly inferior EFS of patients with HOXA9^lo which did not reach statistical significance in a log rank test (p = 0.6929).

(C and D) Patients with HOXA9^lo have a higher median IRX1 (p = 0.012) (C) but not EGR3 gene expression (p = 0.5397) (D) than patients with HOXA9^hi. Significance was tested with two-tailed unpaired t tests.